Chronic Spontaneous Urticaria Market Heats Up as Pharma Companies Race to Address Unmet Needs

PR Newswire··Read original
2▲6 ▼0Impact / 5
Summary · why it matters

The chronic spontaneous urticaria market across the seven major markets reached approximately 2 billion dollars in 2025, with the United States holding the largest share. Total diagnosed prevalent cases of chronic urticaria in those markets were about 4.8 million in 2025 and are expected to rise by 2036. Key companies advancing new therapies include Celldex Therapeutics, Sanofi, Jasper Therapeutics, Evommune, Blueprint Medicines, ARS Pharmaceuticals, Nurix Therapeutics, InflaRx, and Otsuka Holdings through Taiho Pharmaceutical. Promising pipeline candidates such as barzolvolimab, rilzabrutinib, briquilimab, EVO756, BLU-808, ARS-1, bexobrutideg, INF904, and TAS5315 are in clinical development, while recent approvals of DUPIXENT and RHAPSIDO have already broadened treatment options beyond traditional anti-IgE biologics.

Impact on assets 9

Biotech & Genomic Medicine▲ · 6 stocks
Evommune, Inc.
EVMN
▲ PositiveTechnologyrelevance

Evommune's EVO756 is a promising pipeline candidate in the growing CSU market.

Jasper Therapeutics Inc
JSPR
▲ PositiveTechnologyrelevance

Jasper's briquilimab is a promising pipeline candidate in the growing CSU market.

Nurix Therapeutics Inc
NRIX
▲ PositiveTechnologyrelevance

Nurix's bexobrutideg is a promising pipeline candidate in the growing CSU market.

Otsuka Holdings Co., Ltd.
4578
± MixedTechnologyrelevance

Otsuka's Taiho Pharmaceutical has a pipeline candidate TAS5315 in development, but no specific data or milestone is reported.

Health Care▲ · 3 stocks
Sanofi SA
SAN
▲ PositiveDemandrelevance

Sanofi's DUPIXENT is mentioned as a recent approval broadening treatment options, indicating market adoption and demand.

Off-coverage companies 1

Blueprint Medicines CorporationPrivate± Mixed
Technologyrelevance

Blueprint Medicines has a pipeline candidate BLU-808 in clinical development, but no specific data or milestone is reported.

© 2026 MarketIVNews